Business Wire

Servier announces European Commission decision to convert conditional approval into standard marketing authorization in patients with aggressive non-Hodgkin B-cell lymphoma for PIXUVRI® (pixantrone)

Share

Servier today announced that the European Commission (EC) has approved the conversion of the conditional approval of PIXUVRI® (pixantrone) into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.

“There are limited treatment options for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma,” said Prof Pier Luigi Zinzani from the University of Bologna Institute of Hematology and Medical Oncology in Bologna, Italy. “PIXUVRI has demonstrated efficacy in late stage disease and the EC approval confirms PIXUVRI as a treatment option for these patients.”

The EC approval is based on data from the global clinical development of PIXUVRI.

The pivotal study, PIX301 was an open-label, randomized, Phase III study comparing PIXUVRI monotherapy with physician's choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab. PIXUVRI was shown to be beneficial in these patients: 20% of patients responded completely to PIXUVRI compared with 5.7% of patients receiving other agents (p=0.021).1,2

To satisfy requirements of the conditional authorization, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of PIXUVRI in patients that had received prior treatment regimens containing rituximab. In the study PIX306, all patients were previously treated with rituximab. While the superiority of PIXUVRI with rituximab compared to gemcitabine with rituximab was not met, both progression-free survival and overall survival results in patients with ≥ 2 prior treatment lines were similar, when indirectly compared to the PIXUVRI treated population in the pivotal study PIX301.2,3

“At Servier, we work diligently to develop and deliver medicines that address critical unmet medical needs in diseases such as multiply relapsed or refractory aggressive non-Hodgkin lymphoma,” said Patrick Therasse, Head of Servier Research and Development Oncology. “PIXUVRI has been benefitting patients since its conditional approval in 2012 but today’s decision brings reassurance to patients and clinicians that this medicine remains a relevant treatment option in this indication.”

The most common side effects with PIXUVRI are neutropenia, leukopenia, lymphopenia, anemia, thrombocytopenia, nausea, vomiting, skin discolouration, alopecia, chromaturia and asthenia.1

#ENDS#

About non-Hodgkin lymphoma (NHL)

NHL is a blood cancer that affects the lymphatic system, which is defined as a network of vessels and glands that run throughout the body.4 The lymphatic system is a key component of the immune system, as it plays a role in destroying old or abnormal cells and fighting bacteria and other infections.5

NHL can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.6 Around 168,000 new cases of NHL are diagnosed in the United States and Europe every year.

About PIXUVRI (pixantrone)

PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.7 PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.8

PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.9

More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.

Servier commercializes PIXUVRI under a license from CTI BioPharma.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Find us on Social Media:

1 European Medicines Agency. Pixuvri SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf [last accessed May 2019].

2 Pettengell, R. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13: 696–706

3 Salles, G.A, et al. Results of a phase 3 randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation. American Society Hematology annual congress 2018. P4189.

4 NHS Conditions webpage. NHL Cancer. Available at http://www.nhs.uk/Conditions/non-hodgkins-lymphoma/Pages/Definition.aspx [last accessed May 2019].

5 Cancer Research UK. Lymphatic System. Available at http://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-lymphatic-system-and-cancer [last accessed May 2019].

6 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma [last accessed May 2019].

7 Pixuvri Summary of Product Characteristics, Available at: https://www.medicines.org.uk/emc/medicine/29829 [last accessed May 2019].

8 European Medicines Agency. Summary of the European public assessment report (EPAR) for Pixuvri. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri [last accessed May 2019].

9 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma [last accessed May 2019].

Contact information

Servier Media Relations
Sonia MARQUES: media@servier.com
Tel.: +33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13

Jean-Clément VERGEAU: media@servier.com
Tel.: +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Denodo Announces DataFest 2019 in London: Third Annual Conference in Europe for Data Professionals Provides Valuable Insights on Machine Learning, Cloud and Advanced Analytics18.10.2019 06:15:00 CESTPress release

Denodo, the leader in data virtualization, announced its 3rd annual user conference in Europe, Denodo DataFest, on 23rd October in London. In this conference, attendees will learn strategies on how to leverage data virtualization to enable highly flexible, agile, and powerful BI architectures that are paving the way to multi-cloud adoption. The event can be attended in person or online by connecting to the live stream. “I am looking forward to speaking at the Denodo DataFest 2019 user conference and am excited to share how we are using data virtualization to enable self-service BI for business users at Festo,” said Diethard Frank, IT Product Manager, Big Data & AI Services at Festo. “I’m excited to share our experience and lessons learned that will hopefully help other organizations think about how to leverage modern technology approaches to truly innovate and uncover hidden value from their data.” Through this immersive conference, Denodo is bringing together visionary leaders and tec

STALICLA Appoints Stéphane Baudouin as Chief of Science17.10.2019 22:01:00 CESTPress release

STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA). STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/ STALICLA's Chief of Science - Stéphane Baudouin (Photo: STALICLA) Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior

Laser System Partnership Sets Sights on Ending Toll Road Delays17.10.2019 22:00:00 CESTPress release

A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics. Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions. Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.

IFF to Release Third Quarter 2019 Results November 417.10.2019 20:15:00 CESTPress release

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its third quarter 2019 earnings results following the market close on Monday, November 4, 2019. The management team will host a live webcast on Tuesday, November 5, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.co

PTC Launches Global Event Series with FT Live to Help Industrial Enterprises Embrace Digital Transformation17.10.2019 18:00:00 CESTPress release

PTC (NASDAQ: PTC) today announced the launch of Digital Transformation: The New Reality World Tour, a new event program that extends the excitement of the annual PTC LiveWorx® event. The new event program features the debut of the FT-PTC Future of Industrial Innovation Global Series, produced with FT Live, the global events arm of the Financial Times. As a component of The New Reality World Tour program, this insightful series will empower leaders of industrial companies to achieve success with their digital transformation strategies. According to McKinsey & Company, more than 70% of large-scale digital transformation efforts are likely to fail due to a lack of executive sponsorship, imprecise business cases, and delayed technology implementation. The New Reality World Tour program guides stakeholders of all levels, from the C-suite to the frontline worker, through these potential hurdles, enabling industrial enterprises to succeed with digital transformation. “The New Reality World To

Pioneer Cement of UAE to Develop US$200 Million Greenfield Cement Project in Georgia17.10.2019 17:49:00 CESTPress release

The UAE based Pioneer Cement Industries (“Pioneer Cement”), part of Oman based Raysut Cement Company SAOG (RCC) is in the process of setting up a 1.2 m tonnes per annum capacity integrated cement plant in Georgia, Eastern Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005812/en/ Mr. Joey Ghose, RCC Group CEO (Photo : AETOSWire) Pioneer Cement owns concession to limestone mines in Georgia that will provide the key raw materials to this project. Georgia provides Pioneer Cement an opportunity to diversify from the Middle East into a market with large infrastructure growth and shortage of clinker and high-quality cement, the company said in a statement. The plant will be located near Tbilisi, adjacent to the limestone mines. The debt and equity arrangements for the project are currently being finalized and the construction work in the project is slated to commence from Q4 2019. The value of the project is estimated